CRISPR/Cas9 technology generated a T to C point mutation at position 716 (c.716T>C) resulting in a leucine to proline change at amino acid 239 (p.Leu239Pro) using gRNA 5'-TCCGCCGCTTCTGCTTCAGG-3'. Focal segmental glomerulosclerosis affected individuals harbor this rare heterozygous substitution.